{
    "Clinical Trial ID": "NCT00357110",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Fulvestrant + Anastrozole",
        "  fulvestrant 500 mg + anastrozole 1 mg",
        "INTERVENTION 2: ",
        "  Anastrozole",
        "anastrozole 1 mg"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Postmenopausal women with hormone receptor-positive early breast cancer and a positive Disseminated Tumour Cell immunocytochemical result from bone marrow aspiration prior to randomisation",
        "Exclusion Criteria:",
        "  Inflammatory and/or metastatic breast cancer.",
        "  Current or previous malignancy within previous 5 years (other than Breast cancer or adequately treated non-melanoma skin cancer or in-situ cervical cancer).",
        "  History of bleeding diathesis."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence)",
        "  Number of patients event-free",
        "  Time frame: 12 month period following randomisation",
        "Results 1: ",
        "  Arm/Group Title: Fulvestrant + Anastrozole",
        "  Arm/Group Description: fulvestrant 500 mg + anastrozole 1 mg",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  6",
        "Results 2: ",
        "  Arm/Group Title: Anastrozole",
        "  Arm/Group Description: anastrozole 1 mg",
        "  Overall Number of Participants Analyzed: 7",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  7"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/6 (16.67%)",
        "  Goitre 0/6 (0.00%)",
        "  Haemorrhoid Operation 0/6 (0.00%)",
        "  Sciatica 0/6 (0.00%)",
        "  Renal Failure 0/6 (0.00%)",
        "  Varicose Vein 1/6 (16.67%)",
        "Adverse Events 2:",
        "  Total: 2/7 (28.57%)",
        "  Goitre 1/7 (14.29%)",
        "  Haemorrhoid Operation 1/7 (14.29%)",
        "  Sciatica 1/7 (14.29%)",
        "  Renal Failure 1/7 (14.29%)",
        "  Varicose Vein 0/7 (0.00%)"
    ]
}